首页> 外文OA文献 >FRI0315 Safety, tolerability, pharmacokinetic and pharmacodynamic effects of biib059, a monoclonal antibody targeting bdca2 following intravenous (IV) and subcutaneous (SC) single or multiple doses administration in healthy volounteers (HV) and subjects with active systemic lupus erythematosus (SLE)

【2h】

FRI0315 Safety, tolerability, pharmacokinetic and pharmacodynamic effects of biib059, a monoclonal antibody targeting bdca2 following intravenous (IV) and subcutaneous (SC) single or multiple doses administration in healthy volounteers (HV) and subjects with active systemic lupus erythematosus (SLE)

机译：Fri0315 BiiB059的安全性，耐受性，药代动力学和药效学和药效动性效应，静脉注射（IV）和皮下（SC）单或多剂量给药在健康卷（HV）和有活性系统狼疮（SLE）中的受试者（SLE）

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
C. Barbey; H. Naik; C. Musselli; R. Christmann; L. Stevenson; D. Rabah; P. Gulati; N. Franchimont;
展开▼
作者单位

展开▼
年度 2018
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献

1. BIIB059, a monoclonal antibody targeting BDCA2, decreases Type I Interferon-related genes transcriptional activity in subjects with systemic lupus erythematosus (SLE) and active cutaneous LE (CLE) [J] . Werth V. P., Merola J. F., Furie R., The Journal of investigative dermatology. . 2018,第5a19期

机译：靶向BDCA2的单克隆抗体BiiB059，降低了具有全身性狼疮（SLE）和活性皮肤le（CLE）的受试者的I型干扰素相关基因转录活性。
2. Pharmacokinetics and pharmacodynamics of tocilizumab, a humanized anti-interleukin-6 receptor monoclonal antibody, followingsingle-dose administration by subcutaneous and intravenous routes in healthy subjects [J] . ZhangX., GeorgyA., RowellL. International journal of clinical pharmacology and therapeutics . 2013,第6期

机译：ToColizumab的药代动力学和药效学，一种人源化的抗白细胞介素-6受体单克隆抗体，通过皮下和静脉注射治疗的静脉剂量给药
3. Improvement of Disease Activity and Reduction of Severe Flares Following Subcutaneous Administration of an IL-6 Monoclonal Antibody (mAb) in Subjects with Active Generalized Systemic Lupus Erythematosus (SLE) [J] . Wallace Daniel J., Popa Serghei, Spindler Alberto J., Arthritis & rheumatology. . 2014,第12期

机译：在患有活动性全身性系统性红斑狼疮（SLE）的受试者中皮下注射IL-6单克隆抗体（mAb）后，疾病活动性的改善和严重发作的减少
4. An Exploratory Dose-Escalating Study Investigating the Safety Tolerability Pharmacokinetics and Pharmacodynamics of Intravenous Atacicept in Patients with Systemic Lupus Erythematosus [O] . C Pena-Rossi, E Nasonov, M Stanislav, -1

机译：探索性剂量递增研究研究系统性红斑狼疮患者静脉注射阿西西普的安全性耐受性药代动力学和药效学
5. OP0193 BIIB059, A HUMANIZED MONOCLONAL ANTIBODY TARGETING BDCA2 ON PLASMACYTOID DENDRITIC CELLS (PDC), SHOWS DOSE-RELATED EFFICACY IN THE PHASE 2 LILAC STUDY IN PATIENTS (PTS) WITH ACTIVE CUTANEOUS LUPUS ERYTHEMATOSUS (CLE) [O] . V. Werth, R. Furie, J. Romero-Diaz, 2020

机译：OP0193 BiiB059，靶向BDCA2的靶标曲面细胞（PDC）的人源化单克隆抗体，显示出在患者（PTS）的2次淡紫色研究中的剂量有关的功效，具有活跃的皮肤红斑狼疮（CLE）

著录项

引文网络

相似文献

相关主题

期刊订阅